Galectin Therapeutics Inc. recently held a KOL Event Presentation focusing on Belapectin, a galectin-3 inhibitor, for MASH cirrhosis and portal hypertension. The event featured discussions led by industry experts, including Joel Lewis, the CEO and President, and Khurram Jamil, M.D., the Chief Medical Officer. Key highlights included the potential of Belapectin to reduce galectin-3 expression and fibrogenic activity, as evidenced by pre-clinical studies. The phase 2b trial (GT-026) demonstrated that a 2 mg dose of Belapectin significantly improved portal pressure and reduced the incidence of esophageal varices in patients without baseline varices over 52 weeks. The presentation underscored the significant unmet need in the treatment of compensated MASH cirrhosis with portal hypertension, as no FDA-approved therapies currently exist to reverse fibrosis in this condition. You can access the full presentation through the link below.